D. Powell

发表

Therapeutic dendritic cell-based cancer vaccines: the state of the art.

M. Strioga, T. Felzmann, D. Powell, 2013, Critical reviews in immunology.

Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer

Brian J. Stevenson, D. Torigian, H. Nisenbaum, 2018, Science Translational Medicine.

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

V. Beral, R. Bast, D. Bowtell, 2015, Nature Reviews Cancer.

Partial Reduction of Human FOXP3+ CD4 T Cells In Vivo After CD25-directed Recombinant Immunotoxin Administration

S. Rosenberg, D. Powell, V. Ghetie, 2008, Journal of immunotherapy.

Structures of MART-126/27-35 Peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition.

Brian M Baker, D. Powell, B. Baker, 2007, Journal of molecular biology.

CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape

D. Powell, A. Palazón, A. Rodríguez-García, 2020, Frontiers in Immunology.

Persistence of Tumor Infiltrating Lymphocytes in Adoptive Immunotherapy Correlates With Telomere Length

S. Rosenberg, D. Powell, P. Robbins, 2007, Journal of immunotherapy.

Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor.

G. Coukos, D. Powell, R. Sandaltzopoulos, 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells

D. Powell, C. June, S. Albelda, 2013 .

IL-21 promotes the expansion of CD27+CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells

D. Powell, C. June, T. D. de Gruijl, 2013, Journal of Translational Medicine.

Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes

G. Coukos, D. Powell, B. Levine, 2011, Journal of Translational Medicine.

Multiparameter comparative analysis reveals differential impacts of various cytokines on CART cell phenotype and function ex vivo and in vivo

D. Powell, Qunrui Ye, Yongmin Tang, 2016, Oncotarget.

Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy

G. Coukos, D. Powell, C. June, 2011, Journal of Translational Medicine.

Systematic analysis of CD39, CD103, CD137, and PD‐1 as biomarkers for naturally occurring tumor antigen‐specific TILs

D. Powell, Jessica Chacon, Monika A. Eiva, 2021, European journal of immunology.

Chimeric Antigen Receptor T-Cells: New Approaches to Improve Their Efficacy and Reduce Toxicity

D. Powell, M. Maus, D. Powell, 2015, Cancer journal.

Strain-dependent Lethal Toxicity in NKG2D Ligand-targeted CAR T-cell Therapy.

D. Powell, Rachel C. Lynn, 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

A human ErbB2-specific T-cell receptor confers potent antitumor effector functions in genetically engineered primary cytotoxic lymphocytes.

B. Czerniecki, D. Powell, P. Robbins, 2014, Human gene therapy.

In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB).

G. Coukos, D. Powell, C. June, 2011, Cancer research.

Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study.

R. Burger, D. Powell, M. Feldman, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level

D. Powell, Qunrui Ye, M. Figini, 2016, Journal of Hematology & Oncology.

Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo

Raphael Sandaltzopoulos, D. Powell, C. June, 2013, Cancer Immunology Research.

CAR T Cells Targeting MISIIR for the Treatment of Ovarian Cancer and Other Gynecologic Malignancies.

D. Powell, G. Adams, M. Robinson, 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

206. Follicle-Stimulating Hormone Receptor as a Target in the Redirected T-Cell Therapy for Cancer

D. Powell, K. Urbańska, Caitlin Stashwick, 2015 .

Follicle-Stimulating Hormone Receptor as a Target in the Redirected T-cell Therapy for Cancer

D. Powell, K. Urbańska, M. Poussin, 2015, Cancer Immunology Research.

CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor

G. Coukos, D. Powell, Chunsheng Li, 2013, Clinical Cancer Research.

FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions.

M. Merino, S. Rosenberg, D. Powell, 2008, Blood.

Inability to Mediate Prolonged Reduction of Regulatory T Cells After Transfer of Autologous CD25-depleted PBMC and Interleukin-2 After Lymphodepleting Chemotherapy

S. Rosenberg, D. Powell, M. Ahmadzadeh, 2007, Journal of immunotherapy.

Lymphodepletion Patients with Metastatic Melanoma following Peripheral Blood Mononuclear Cells to Adoptive Transfer of Vaccine-Induced

S. Rosenberg, D. Powell, M. Dudley, 2006 .

Adoptive Transfer of Vaccine-Induced Peripheral Blood Mononuclear Cells to Patients with Metastatic Melanoma following Lymphodepletion1

S. Rosenberg, D. Powell, M. Dudley, 2006, The Journal of Immunology.

Selective Elimination of Human Regulatory T Lymphocytes In Vitro With the Recombinant Immunotoxin LMB-2

I. Pastan, S. Rosenberg, D. Powell, 2006, Journal of immunotherapy.

Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy.

S. Rosenberg, D. Powell, P. Robbins, 2005, Blood.

Large-Scale Depletion of CD25+ Regulatory T Cells from Patient Leukapheresis Samples

S. Rosenberg, D. Powell, L. Parker, 2005, Journal of immunotherapy.

Transfer Therapy Cancer Regression in Patients Receiving Cell Lymphocyte Clonotypes Correlates with Cutting Edge: Persistence of Transferred

S. Rosenberg, D. Powell, P. Robbins, 2004 .

Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells

D. Powell, D. Song, Yali Han, 2018, Journal of Hematology & Oncology.

A Thyroid Tumor-Specific Antigen Formed by the Fusion of Two Self Proteins1

D. Powell, L. Eisenlohr, J. Rothstein, 2003, The Journal of Immunology.

VivoPartial Reduction in Regulatory T Cells In Metastatic Melanoma Induces a Selective Immunotoxin, LMB-2, to Patients with Administration of a CD25-Directed

I. Pastan, M. Merino, S. Rosenberg, 2007 .

Administration of a CD25-Directed Immunotoxin, LMB-2, to Patients with Metastatic Melanoma Induces a Selective Partial Reduction in Regulatory T Cells In Vivo1

I. Pastan, M. Merino, S. Rosenberg, 2007, The Journal of Immunology.

Humanized Patient-Derived Xenograft Models of Ovarian Cancer.

D. Powell, F. Simpkins, Sarah B. Gitto, 2021, Methods in molecular biology.

Phenotypic and Functional Maturation of Tumor Antigen-Reactive CD8+ T Lymphocytes in Patients Undergoing Multiple Course Peptide Vaccination

S. Rosenberg, D. Powell, D. Powell, 2004, Journal of immunotherapy.

Altered gene expression in immunogenic poorly differentiated thyroid carcinomas from RET/PTC3p53−/− mice

K. Huebner, D. Powell, J. Rothstein, 2001, Oncogene.

PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor Response

R. Mach, D. Powell, Hwan Lee, 2020, Molecules.

Rech in Concert with Immunotherapy in Cancer Patients CD 25 Blockade Depletes and Selectively Reprograms Regulatory T Cells

A. DeMichele, D. Powell, K. Fox, 2012 .

Dendritic cells and their role in tumor immunosurveillance

M. Strioga, D. Powell, N. Dobrovolskienė, 2013, Innate immunity.

A CD45RO+ stem cell memory T cell population intermediate to canonical stem cell memory and central memory T cells in human cancer.

Aaron M. Rosenfeld, D. Powell, W. Meng, 2022 .

Efficient clinical-scale enrichment of lymphocytes for use in adoptive immunotherapy using a modified counterflow centrifugal elutriation program.

D. Powell, B. Levine, Zhaohui Zheng, 2009, Cytotherapy.

Advances and prospects in adoptive cell transfer therapy for ovarian cancer.

D. Powell, K. Urbańska, D. Powell, 2015, Immunotherapy.

Day-4 Myeloid Dendritic Cells Pulsed with Whole Tumor Lysate Are Highly Immunogenic and Elicit Potent Anti-Tumor Responses

G. Coukos, B. Czerniecki, D. Powell, 2011, PloS one.

MYELOID NEOPLASIA Targeting of folate receptor b on acute myeloid leukemia blasts with chimeric antigen receptor – expressing T cells

P. Low, D. Dimitrov, D. Powell, 2015 .

Folate Receptor Beta as a Direct and Indirect Target for Antibody-Based Cancer Immunotherapy

D. Powell, M. Poussin, C. Nickerson-Nutter, 2021, International journal of molecular sciences.

Pro-survival signaling via CD27 costimulation drives effective CAR T-cell therapy

D. Powell, D. Song, 2012, Oncoimmunology.

D. Powell, D. Song, 2012 .

Transfer Therapy Cancer Regression in Patients Receiving Cell Lymphocyte Clonotypes Correlates with Cutting Edge: Persistence of Transferred

S. Rosenberg, D. Powell, P. Robbins, 2022 .

through following

G. Mills, E. Kohn, R. Bast, 2019 .

Induction of IL19 expression through JNK and cGAS-STING modulates DNA damage–induced cytokine production

D. Powell, E. Brown, R. Mandal, 2021, Science Signaling.

Adoptive immunotherapy for cancer: building on success

S. Rosenberg, D. Powell, N. Restifo, 2006, Nature Reviews Immunology.

Pre-clinical investigation of astatine-211-parthanatine for high-risk neuroblastoma

Ji Youn Lee, R. Mach, J. Maris, 2022, Communications Biology.

Epigenetic state determines inflammatory sensing in neuroblastoma

Liron D. Grossmann, Yasin Uzun, C. Dang, 2021, Proceedings of the National Academy of Sciences.

A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor.

D. Powell, K. Urbańska, Rachel C. Lynn, 2012, Cancer research.

Feasibility and Safety of RNA-transfected CD20-specific Chimeric Antigen Receptor T Cells in Dogs with Spontaneous B Cell Lymphoma.

D. Powell, J. Smith, N. Mason, 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

An autologous humanized patient-derived-xenograft platform to evaluate immunotherapy in ovarian cancer.

D. Powell, Hyoung Kim, F. Simpkins, 2019, Gynecologic oncology.

Engineering enhanced CAR T-cells for improved cancer therapy

D. Powell, J. Melenhorst, McKensie A. Collins, 2021, Nature Cancer.

The Emergence of Universal Immune Receptor T Cell Therapy for Cancer

D. Powell, Nicholas G. Minutolo, Erin E. Hollander, 2019, Front. Oncol..

CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy

D. Powell, Rachel C. Lynn, Roddy S. O’Connor, 2021, Nature communications.

A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer

G. Coukos, D. Powell, L. Kandalaft, 2012, Journal of Translational Medicine.

Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor

Jing Sun, Carl H. June, James L. Riley, 2011, Clinical Cancer Research.

High affinity FRβ-specific CAR T cells eradicate AML and normal yeloid lineage without HSC toxicity

D. Dimitrov, D. Powell, Yang Feng, 2016, Leukemia.

Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors.

D. Jackson, M. Delorenzi, Lin Zhang, 2019, Cancer cell.

T-cell target antigens across major gynecologic cancers.

D. Powell, J. M. Robinson, A. Rodríguez-García, 2017, Gynecologic oncology.

A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity

D. Powell, Qunrui Ye, M. Figini, 2015, Oncotarget.

Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference

G. Mills, E. Kohn, R. Bast, 2019, Cancer.

Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer

Brian J. Stevenson, D. Torigian, H. Nisenbaum, 2021, NPJ vaccines.

Systematic evaluation of multiple immune markers reveals prognostic factors in ovarian cancer.

D. Powell, M. Feldman, J. Tanyi, 2016, Gynecologic oncology.

Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses.

D. Powell, R. Sandaltzopoulos, Aizhi Zhao, 2013, Cancer research.

Therapeutics , Targets , and Chemical Biology Novel Recombinant Human B 7-H 4 Antibodies Overcome Tumoral Immune Escape to Potentiate T-Cell Antitumor Responses

D. Powell, R. Sandaltzopoulos, Aizhi Zhao, 2013 .

Tumor infiltrating lymphocytes in ovarian cancer

D. Powell, Daniel J Powell, P. Santoiemma, 2015, Cancer biology & therapy.

Adoptive immunotherapy: good habits instilled at youth have long-term benefits

Bruce L. Levine, Gabriela Plesa, Chrystal M. Paulos, 2008, Immunologic research.

PTEN Loss and BRCA1 Promoter Hypermethylation Negatively Predict for Immunogenicity in BRCA-Deficient Ovarian Cancer

K. Nathanson, J. Pluta, D. Powell, 2022, JCO precision oncology.

Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation.

Santiago J. Carmona, P. Sorger, M. Delorenzi, 2021, Cancer cell.

Immunotherapy for ovarian cancer: what's next?

G. Coukos, D. Powell, L. Kandalaft, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genetically Engineered Antigen Specificity in T Cells for Adoptive Immunotherapy

D. Powell, B. Levine, D. Powell, 2011 .

Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cells.

S. Rosenberg, D. Powell, R. Morgan, 2008, Human gene therapy.

Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting

B. Garcia, G. Linette, D. Powell, 2021, Nature Communications.

Primary Human Ovarian Epithelial Cancer Cells Broadly Express HER2 at Immunologically-Detectable Levels

G. Coukos, D. Powell, R. Sandaltzopoulos, 2012, PloS one.

BRCA Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian Cancer.

R. Burger, J. Reis-Filho, B. Weigelt, 2020, JCO precision oncology.

Quantitative Control of Gene-Engineered T cell Activity Through Covalent Attachment of Targeting Ligands to a Universal Immune Receptor.

D. Powell, A. Tsourkas, J. Z. Hui, 2020, Journal of the American Chemical Society.

Adoptive T-cell therapy for malignant disorders

D. Powell, B. Levine, D. Powell, 2008, Haematologica.

New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer

F. Marincola, J. Heath, S. Rosenberg, 2012, Journal of Translational Medicine.

CD25 Blockade Depletes and Selectively Reprograms Regulatory T Cells in Concert with Immunotherapy in Cancer Patients

A. DeMichele, D. Powell, K. Fox, 2012, Science Translational Medicine.

The Impact of Chemotherapy, Radiation and Epigenetic Modifiers in Cancer Cell Expression of Immune Inhibitory and Stimulatory Molecules and Anti-Tumor Efficacy

D. Powell, K. Schutsky, Jessica A. Chacon, 2016, Vaccines.

The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids.

D. Powell, M. Santoro, A. Fusco, 1998, Cancer research.

Gene Transfer of Tumor-Reactive TCR Confers Both High Avidity and Tumor Reactivity to Nonreactive Peripheral Blood Mononuclear Cells and Tumor-Infiltrating Lymphocytes1

S. Rosenberg, D. Powell, R. Morgan, 2006, The Journal of Immunology.

The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.

G. Coukos, J. Berek, D. Powell, 2010, Gynecologic oncology.

Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18

P. Gimotty, G. Coukos, D. Powell, 2009, Journal of Translational Medicine.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

T Cells Bearing a Chimeric Antigen Receptor against Prostate-Specific Membrane Antigen Mediate Vascular Disruption and Result in Tumor Regression

G. Coukos, D. Powell, Stephen P. Santoro, 2014, Cancer Immunology Research.

NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma

D. Powell, D. Megías, O. Graña-Castro, 2021, Blood Cancer Journal.

Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer

Drew A. Torigian, Lana E. Kandalaft, George Coukos, 2013, Oncoimmunology.

Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor

D. Powell, Rachel C. Lynn, Yangbing Zhao, 2015, Oncotarget.

CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo.

D. Powell, Qunrui Ye, M. Figini, 2012, Blood.

Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy.

D. Powell, D. Dangaj, N. Scholler, 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

B7-H4 as a potential target for immunotherapy for gynecologic cancers: a closer look.

D. Powell, J. Smith, Caitlin Stashwick, 2014, Gynecologic oncology.

T-cell immunotherapy: looking forward.

D. Baltimore, A. Ribas, S. Rosenberg, 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

Activated and Expanded Natural Killer Cells Expressing an NKG2D-CAR Efficiently Target Multiple Myeloma Cells

D. Powell, Dean Anthony Lee, J. Lahuerta, 2017 .

The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium

Angela Greco, Giuseppe Portella, D. Powell, 2000, Oncogene.

Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity

S. Rosenberg, D. Powell, R. Nussenblatt, 2008, Proceedings of the National Academy of Sciences.

Targeting of folate receptor β on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells.

P. Low, D. Dimitrov, D. Powell, 2015, Blood.

Highlights of the society for immunotherapy of cancer (SITC) 27th annual meeting

F. Marincola, R. Puri, L. Zitvogel, 2013, Journal of Immunotherapy for Cancer.

Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells

D. Powell, K. Urbańska, A. Thakur, 2014, Journal of Translational Medicine.

Development of a novel universal immune receptor for antigen targeting

D. Powell, K. Urbańska, D. Powell, 2012, Oncoimmunology.

Lymphocytes Mononuclear Cells and Tumor-Infiltrating Reactivity to Nonreactive Peripheral Blood Confers Both High Avidity and Tumor Gene Transfer of Tumor-Reactive TCR

S. Rosenberg, D. Powell, R. Morgan, 2006 .

T-Cell Immunotherapy: Looking Forward: T Cell Immunotherapy: Optimizing Trial Design Bethesda, Maryland 10-11 September 2013.

D. Baltimore, A. Ribas, S. Rosenberg, 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

A Dendritic Cell Vaccine Pulsed with Autologous Hypochlorous Acid-Oxidized Ovarian Cancer Lysate Primes Effective Broad Antitumor Immunity: From Bench to Bedside

Drew A. Torigian, Lana E. Kandalaft, George Coukos, 2013, Clinical Cancer Research.

Exploring NKG2D and BCMA-CAR NK-92 for Adoptive Cellular Therapy to Multiple Myeloma

D. Powell, M. Cedena, J. Martínez-López, 2019, Clinical Lymphoma Myeloma and Leukemia.

T Cell Immunotherapy: Optimizing Trial Design

D. Baltimore, A. Ribas, S. Rosenberg, 2014 .

CD4+ T-Helper Type 1 Cytokines and Trastuzumab Facilitate CD8+ T-cell Targeting of HER2/neu–Expressing Cancers

B. Czerniecki, D. Powell, Shuwen Xu, 2015, Cancer Immunology Research.

Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition.

D. Powell, Stephen P. Santoro, Qunrui Ye, 2013, Human gene therapy.

CD 27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo

D. Powell, Qunrui Ye, M. Figini, 2012 .

Remarkable stability of clinical grade reagents for gene-engineered T-lymphocyte production.

D. Powell, L. Johnson, 2013, Cytotherapy.

The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28–Costimulated T Cells Prepared for Adoptive Therapy

F. Marincola, G. Coukos, D. Powell, 2015, Clinical Cancer Research.

Systematic analysis of CD39, CD103, CD137 and PD-1 as biomarkers for naturally occurring tumor antigen-specific TILs

D. Powell, Monika A. Eiva, Dalia K Omran, 2021, bioRxiv.

Autologous whole-tumor antigen vaccination in combination with adoptive T cell therapy for patients with recurrent ovarian cancer

G. Coukos, D. Powell, J. Tanyi, 2013, Journal of Immunotherapy for Cancer.

Abstract LB-335: Autologous whole-tumor antigen vaccination in combination with adoptive T cell therapy for patients with recurrent ovarian cancer.

G. Coukos, D. Powell, J. Tanyi, 2013 .

Mannose Receptor (MR) Engagement by Mesothelin GPI Anchor Polarizes Tumor-Associated Macrophages and Is Blocked by Anti-MR Human Recombinant Antibody

D. Powell, R. Sandaltzopoulos, Aizhi Zhao, 2011, PloS one.

A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer

G. Coukos, D. Powell, L. Kandalaft, 2012, Journal of Translational Medicine.

431 First-in-human phase I clinical trial evaluating intraperitoneal administration of MOv19-BBz CAR T cells in patients with alpha folate receptor-expressing recurrent high grade serous ovarian cancer

G. Coukos, D. Powell, S. Canevari, 2021, Journal for ImmunoTherapy of Cancer.

Of mice and men: pre-clinical models to identify therapy responsive patient subgroups

D. Powell, Sarah B Gitto, D. Powell, 2020, Gynecology and Pelvic Medicine.

Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th–December 1st, 2022)

P. Ascierto, T. Kirchhoff, B. Fox, 2023, Journal of Translational Medicine.

A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.

D. Torigian, H. Nisenbaum, G. Coukos, 2013, Clinical cancer research : an official journal of the American Association for Cancer Research.

TCRvβ-CART therapy mediates high-precision targeting of malignant T-cell clones

D. Powell, S. Schuster, A. Rook, 2022, Blood advances.

The spectrum of MAPK-ERK pathway genomic alterations in gynecologic malignancies: Opportunities for novel therapeutic approaches

M. Carey, D. Powell, S. Westin, 2023, Gynecologic Oncology.

PS1209 NKG2D AND BCMA-CAR NK CELLS EFFICIENTLY ELIMINATE MULTIPLE MYELOMA CELLS. A COMPREHENSIVE COMPARISON BETWEEN TWO CLINICALLY RELEVANT CARS

D. Powell, J. Martínez-López, P. Río, 2019, HemaSphere.

NKG2D-CAR Transduced Primary Natural Killer Cells Efficiently Target Multiple Myeloma Cells

D. Powell, Dean Anthony Lee, J. Martínez-López, 2018, Blood.